welcome to the 70h megathread. everything you ever need to know about 7oh in one spot.
let's start from the beginning-
Kratom comes from the leaves of Mitragyna speciosa, a tree native to Southeast Asia. For generations it was traditionally used in the region, typically by chewing the leaves or brewing them into tea. The plant contains dozens of alkaloids, with mitragynine being the most abundant. Kratom products began appearing more widely in the United States in the late 1990s and early 2000s, initially among immigrant communities and later through online and specialty retailers.
7-hydroxymitragynine (7OH) is a minor alkaloid that occurs naturally in kratom leaves in only trace amounts. It is also produced in the body when mitragynine is metabolized by the liver. Researchers first isolated and identified it in 1994. Because natural levels are so low, 7OH remained largely a scientific footnote for decades. In the mid-2020s, however, manufacturers began concentrating or semi-synthesizing the compound and selling it in higher-potency products such as tablets, gummies, and liquid shots. These concentrated forms quickly entered the U.S. market and drew significant regulatory and public attention.
What 7OH Is — Scientifically and Socially
Scientifically, 7-hydroxymitragynine (7OH) is a terpenoid indole alkaloid with the molecular formula C₂₃H₃₀N₂O₅. It occurs naturally in Mitragyna speciosa leaves only in very small amounts—typically well under 0.05% of the dried leaf weight and rarely more than a couple percent of the total alkaloid content. The same compound is also formed in the human body as an active metabolite when mitragynine, the dominant alkaloid in kratom, is oxidized by liver enzymes (primarily CYP3A4).
The sudden availability of high-potency 7OH products, sometimes marketed in ways that blurred the distinction with traditional kratom leaf, triggered regulatory concern. The FDA issued warning letters, publicly distinguished concentrated 7OH from natural kratom, and recommended scheduling controls targeting elevated levels of the compound. Public debate has centered on potency, accessibility, potential for dependence, and the speed with which a once-obscure metabolite became a mass-market product.
Pharmacology of 7OH
7-hydroxymitragynine acts primarily as a potent partial agonist at the μ-opioid receptor (MOR), the same receptor targeted by classical opioids such as morphine and fentanyl. At the same time, it functions as an antagonist at the δ- and κ-opioid receptors. This mixed profile distinguishes it from many traditional opioids.
In laboratory binding and functional studies, 7OH shows substantially higher affinity and potency at the μ-opioid receptor than its parent compound, mitragynine. Some assays have reported binding affinities roughly an order of magnitude stronger than morphine, though exact numbers vary depending on the experimental system. Because it is only a partial agonist, it does not activate the receptor to the same maximum degree as full agonists like morphine or fentanyl.
A notable feature of 7OH is its signaling bias. It preferentially activates G-protein pathways downstream of the μ-opioid receptor while recruiting the β-arrestin pathway more weakly. Researchers have explored this bias because β-arrestin signaling is associated with some of the classic opioid side effects, including respiratory depression. Whether this property translates into a meaningfully safer profile in humans remains an open question, especially at the high concentrations found in commercial products.
When mitragynine is consumed (as in traditional kratom), a portion is converted in the liver by CYP3A4 enzymes into 7OH. This conversion means that some of the effects attributed to oral kratom are actually mediated by the metabolite rather than by mitragynine itself. In animal models, isolated 7OH produces clear opioid-like effects: analgesia, sedation, and, with repeated administration, tolerance and physical dependence.
Overall, the pharmacology of 7OH places it firmly in the opioid class, but with a receptor and signaling profile that is not identical to classical full agonists.
Regulation of 7OHIn the United States, concentrated 7-hydroxymitragynine products occupy a rapidly evolving regulatory space that is distinct from traditional kratom leaf.
The Food and Drug Administration has taken the position that 7OH is not a lawful dietary supplement ingredient, cannot be added to conventional foods, and is not an approved drug. Beginning in 2025, the FDA issued multiple warning letters to companies marketing tablets, gummies, liquid shots, and other products containing elevated levels of 7OH. The agency has emphasized that these concentrated products are different from natural kratom leaf, which contains only trace amounts of the compound.
In July 2025 the FDA formally recommended that the Drug Enforcement Administration place certain 7OH products under the Controlled Substances Act. By mid-2026 the DEA had initiated the temporary scheduling process for 7-hydroxymitragynine above a specified concentration threshold, along with several related synthetic derivatives. The stated intent of these actions is to target concentrated and semi-synthetic products rather than botanical kratom leaf containing only naturally occurring trace levels of 7OH.
At the state level, a growing number of jurisdictions have enacted their own restrictions or outright bans on 7OH products, creating a patchwork of rules that vary significantly by location. As of late 2026, federal scheduling proceedings remain active, and the legal status of concentrated 7OH continues to shift.
Overall, regulators have drawn a clear line between traditional kratom leaf and the newer, high-potency 7OH formulations that entered the market in the mid-2020s.
There is no reliable national survey data that tracks 7OH usage specifically year-by-year in the United States. Concentrated 7OH products only became widely available around 2024–2025, somost large-scale surveys (like NSDUH) still fold them into the broader “kratom” category.
The strongest public signal of rising 7OH-related activity is U.S. poison center exposure reports for kratom. These numbers rose modestly for years and then surged sharply in 2025 — a jump that multiple official sources (CDC/MMWR and others) explicitly link to the arrival of high-potency 7OH products.
Here’s a clear graph based on that data:
U.S. Poison Center Reports Involving Kratom (2015–2025)
Year | Reports
-------|--------
2015 | 258
2016 | ~400
2017 | ~700
2018 | ~1,100
2019 | ~1,400
2020 | ~1,500
2021 | ~1,600
2022 | ~1,700
2023 | ~1,800
2024 | ~2,100
2025 | 3,434 ← sharp rise coinciding with widespread 7OH products
Here’s a clean, easy-to-read key 7OH statistics:
Poison Center Reports
- 2025: 593 reports specifically coded as involving 7OH
- First half of 2026: 901 reports (already more than all of 2025)
- Monthly reports in early 2026 were roughly double the rate of late 2025
- About 39% had serious health problems
- About 64% needed treatment at a healthcare facility
- About 21% were admitted to the hospital
Broader kratom-related reports hit 3,803 in 2025 and were on track for a large increase in 2026.
Market & Product Availability
- Late 2024 to early 2025: Researchers identified over 300 different 7OH products for sale online
- Most common forms: tablets, liquid shots, and gummies
- Typical strength: 10–80 mg per tablet
- Average price: around $4 per dose
- One large telehealth clinic saw patients mentioning kratom or 7OH rise from **3%** of new patients (Sept 2025) to **14%** (Aug 2026)
- Some clinics now report seeing **10–20 patients per week** who are dependent on or heavily using concentrated 7OH products
- Late 2025: Authorities seized about 73,000 units of 7OH products (valued at roughly $1 million) from three warehouses
- FDA has issued multiple warning letters to companies selling concentrated 7OH tablets, gummies, and shots
Official / Regulatory
- DEA announcement (July 1, 2026):
https://content.govdelivery.com/accounts/USDOJDEA/bulletins/41e9d40 - HHS / FDA statement supporting the DEA action:
https://www.hhs.gov/press-room/hhs-fda-support-dea-7-oh-scheduling.html - FDA page “Hiding in Plain Sight: 7-OH Products” (updated July 2026):
https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products
News Coverage
- WIRED – “The DEA Plans to Ban Opioid-Like Kratom Compound 7-OH” (July 2, 2026):
https://www.wired.com/story/the-dea-plans-to-ban-kratom-compound-7-oh-sold-as-a-gas-station-opioid/ - WIRED – “7-OH Users Are Stockpiling Ahead of a DEA Ban” (July 28, 2026):
https://www.wired.com/story/7-oh-users-brace-for-dea-ban/ - Medical Toxicology – “DEA Begins Schedule I Process for Concentrated 7-OH…”:
https://medicaltoxic.com/news/dea-concentrated-7-oh-schedule-i-poison-center-exposures - Pharmacy Times – “Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk”:
https://www.pharmacytimes.com/view/...ral-leaf-kratom-presents-no-major-health-risk - Psychiatric Times – “Kratom Component in Clinical Trial for Opioid Use Disorder” (Sept 2026):
https://www.psychiatrictimes.com/view/kratom-component-in-clinical-trial-for-opioid-use-disorder - Reuters – “DEA moves to place some strong kratom-related products under strict federal drug controls” (July 1, 2026):
https://www.reuters.com/legal/litig...roducts-under-strict-federal-drug-2026-07-01/
